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AbsTrACT
Non-variceal upper gastrointestinal bleeding remains an 
important emergency condition, leading to significant 
morbidity and mortality. As endoscopic therapy is 
the ’gold standard’ of management, treatment of 
these patients can be considered in three stages: pre-
endoscopic treatment, endoscopic haemostasis and post-
endoscopic management. Since publication of the Asia-
Pacific consensus on non-variceal upper gastrointestinal 
bleeding (NVUGIB) 7 years ago, there have been 
significant advancements in the clinical management of 
patients in all three stages. These include pre-endoscopy 
risk stratification scores, blood and platelet transfusion, 
use of proton pump inhibitors; during endoscopy new 
haemostasis techniques (haemostatic powder spray and 
over-the-scope clips); and post-endoscopy management 
by second-look endoscopy and medication strategies. 
Emerging techniques, including capsule endoscopy 
and Doppler endoscopic probe in assessing adequacy 
of endoscopic therapy, and the pre-emptive use of 
angiographic embolisation, are attracting new attention. 
An emerging problem is the increasing use of dual 
antiplatelet agents and direct oral anticoagulants in 
patients with cardiac and cerebrovascular diseases. 
Guidelines on the discontinuation and then resumption 
of these agents in patients presenting with NVUGIB 
are very much needed. The Asia-Pacific Working Group 
examined recent evidence and recommends practical 
management guidelines in this updated consensus 
statement.
bACkGround
Important advances in the management of non-var-
iceal upper gastrointestinal bleeding (NVUGIB) 
have been made. The concept of pre-endoscopic 
treatment has changed. New devices in endoscopic 
haemostasis have been introduced. The increasing 
use of antiplatelets and anticoagulants has compli-
cated the picture. Endoscopic interventions, such as 
mucosectomy and endoscopic submucosal dissec-
tion, have become standard care. These procedures 
are associated with marked risks of bleeding. For 
these reasons, the Asia-Pacific Working Group felt 
that it was necessary to update their consensus 
recommendations for the management of NVUGIB.
Similar to the previous Asia-Pacific consensus 
statements published in 2011,1 this update aims 
to produce management guidelines for clinicians 
practising in community or referral hospitals. The 
Asia-Pacific Working Group decided that there 
was no need to repeat guideline statements previ-
ously recommended unless there was a change of 
view, but only to highlight recommendations based 
on new evidence reported in the past 5–10 years. 
Therefore, the 2011 consensus recommendations 
that are not dealt with in this update are considered 
to be still valid for the management of NVUGIB. 
The working group continued to use the same 
modified Delphi process as before1 but chose to 
divide the updated consensus into three sections: 
(1) pre-endoscopic management, (2) endoscopic 
management and (3) post-endoscopic management 
of NVUGIB.
MeThods
The Asia-Pacific Working Group of upper gastro-
intestinal bleeding comprises key opinion leaders 
in the region/countries of Asia and Australasia—
namely, Australia, China, Hong Kong, India, 
Japan, Korea, Malaysia, Philippines, Singapore and 
Taiwan. We also invited international experts from 
Europe and North America to share new scientific 
data and discuss the consensus statements. The 
group met during the Asia-Pacific Digestive Week 
2017 in Hong Kong.
Literature search include Medline, EMBASE, 
the Cochrane Central Register of Controlled Trials 
and ISI Web of Knowledge with manual searches 
of bibliographies of key articles and abstracts of 
major gastroenterology conferences held in the past 
5 years, 2012–2017 (Asian Pacific Digestive Week 
(APDW), Digestive Disease Week (DDW), United 
European Gastroenterology Week (UEGW)). Key 
words used included gastrointestinal bleeding, 
peptic ulcer disease and Asia.
The working group members from the 10 coun-
tries and regions mentioned above were selected 
from the scientific committee of the APDW 2017 
for their expertise in areas of NVUGIB, evidence-
based medicine and continuing medical education. 
The preparation committee in this working group 
comprised JJYS, PCYC, FKLC and JYWL, who 
drafted the initial statements based on the literature.
A modified Delphi process was used, and these 
drafted statements were sent to all group members 
for voting before the meeting, together with 
evidence-based reviews and other pertinent 
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literature. Each statement was assessed on a five-point Likert 
scale: (1) accept completely, (2) accept with some reservation, 
(3) accept with major reservation, (4) reject with reservation, 
(5) reject completely. Results and comments were collated by 
emails. A statement was accepted when supported by ≥80% of 
the working group (ie, proportion of the working group voting 
on the 5-point scale for 1 or 2). Statements that did not reach 
consensus support during the first-round voting were modified. 
These modified statements were discussed during the meeting 
in Hong Kong, followed by a second round of voting with elec-
tronic keypads. Participants voted anonymously on statements 
after discussion and provided comments on the wording of the 
statements, which were progressively finalised through two 
separate iterations. If this again failed to reach consensus, the 
statement was rejected.
Each statement was then assessed for level of evidence by the 
following criteria: (a) high level of evidence; further research 
is very unlikely to change our confidence in the estimate of 
effect, (b) moderate level of evidence; further research is likely 
to have an important impact on our confidence in the estimate 
of effect and may change the recommendation and (c) low level 
of evidence; further research is very likely to have an important 
impact on our confidence in the estimate of effect and is likely 
to change the estimate.
The conference was supported by an unrestrictive grant from 
the GI Research Fund of the Institute of Digestive Disease of 
the Chinese University of Hong Kong. Industry support was 
not provided to avoid potential influence on the process of 
consensus development. Mandatory written disclosure of finan-
cial conflicts of interest within 24 months before the meeting 
was obtained from all voting participants.
In this updated consensus meeting, it was decided that the 
statements should focus on guiding clinical management of 
NVUGIB rather than on clarifying clinical concepts. There 
should be minimal overlap or repetition between this updated 
statement and the previous Asia-Pacific consensus on non-var-
iceal upper gastrointestinal bleeding1 unless new evidence had 
arisen that might change the recommendation. The panel also 
decided to report the statements that had not reached consensus 
as these are also considered useful in providing guidelines for the 
clinical management of such patients. Therefore, the first part of 
this report consists of consensus statements categorised under (1) 
pre-endoscopic management, (2) endoscopic management, (3) 
post-endoscopic management. The second part consists of state-
ments that were rejected after deliberations and debate among 
panel members. These latter statements point towards new 
management concepts or strategies, but they are not accepted as 
recommendations because of insufficient evidence in the existing 
literature.
Consensus sTATeMenTs
Pre-endoscopic management
Statement 1: The Glasgow Blatchford Score (GBS) should be used 
in predicting clinical outcome of all patients presenting with upper 
gastrointestinal bleeding (Accept—agreement: 94.5%, level of 
evidence: high)
The most widely validated scoring methods for prediction of 
recurrent bleeding and mortality are the Rockall (RS), GBS and 
AIMS65. Many studies in the past 5 years have compared the 
performance of various scoring systems as a risk stratification 
tool.
The largest study is a multicentre prospective cohort that 
recruited over 3000 patients with UGIB from six hospitals in 
Europe, North America, Asia and Oceania. It compared the 
pre-endoscopy (admission RS, AIMS65 and GBS) and post-en-
doscopy scores (full RS, and Progetto Nazionale Emorragia 
Digestiva (PNED)) for their ability to predict clinical outcome. 
GBS was found to be the best of these scoring systems for 
predicting the need for intervention and mortality.2 GBS also 
out-performed admission RS and AIMS65 in predicting the need 
for endoscopic treatment. GBS ≥7 is the best score to predict 
the requirement for endoscopic treatment. 
Among these four scoring systems, GBS most accurately 
predicts the need for hospital admission and mortality. In 
Korea, a study recruiting 523 patients with NVUGIB concluded 
that GBS predicted the requirement of blood transfusion with 
highest accuracy.3 It was comparable to the full RS and AIMS65 
for predicting 30-day mortality and endoscopic intervention. 
A multicentre cohort study from Korea comparing GBS and 
RS confirmed that GBS was useful in predicting the need for 
hospital-based intervention, and RS was useful for predicting 
outcome.4
A smaller-scale study from Europe comparing GBS, AIMS65 
and RS in 309 patients presenting with UGIB reported that GBS 
was the best for predicting the need for transfusion, identical 
to AIMS65 in predicting endoscopic intervention, and compa-
rable to AIMS65 and RS in predicting inpatient mortality.5
In Denmark, 831 patients with UGIB were enrolled to 
compare the accuracy of GBS, the age-extended GBS, the Baylor 
Bleeding Score and the Cedars-Sinai Medical Centre Predictive 
Index using the outcome of (1) need for hospital-based inter-
vention or 30-day mortality, (2) likelihood of rebleeding and (3) 
mortality.6 GBS accurately identified patients most likely to need 
a hospital-based intervention, but none of these scores accu-
rately predicted mortality or rebleeding.
Two studies from Australia were reported. From Victoria, a 
study comparing AIMS65, GBS and RS in 424 patients confirmed 
that the three scores were comparable in predicting a composite 
outcome of rebleeding and endoscopic/radiological intervention, 
and mortality.7 GBS was the best for predicting blood transfu-
sion. The AIMS65 score was better than both the GBS (area 
under the receiver operating characteristic curve (AUROC), 0.80 
vs 0.76, P<0.027) and the pre-endoscopy RS (AUROC 0.74, 
P=0.001) and equivalent to the full RS (AUROC 0.78, P=0.18) 
in predicting inpatient mortality. The AIMS65 score was better 
than all other scores in predicting the need for intensive care 
unit (ICU) admission and length of hospital stay. In Adelaide, 
comparing just GBS and RS, investigators confirmed that GBS 
was superior in predicting blood transfusion and surgery, and 
was equivalent to RS in predicting the need for endoscopic 
therapy, rebleeding and death.8
A study from Thailand recruiting close to 1000 patients with 
UGIB compared GBS, full RS and pre-endoscopic RS and found 
that these scores were better in NVUGIB than variceal UGIB.9 
In Iran, 200 patients were recruited to compare the prediction 
value of GBS and full RS. GBS was more accurate than full RS 
for need for blood transfusion, rebleeding, ICU admission and 
endoscopic intervention. RS predicted 30-day mortality better 
than GBS in this study.10
A systematic review identified 16 studies evaluating pre-en-
doscopic risk scores (GBS, RS and AIMS65) on a composite 
outcome including recurrent bleeding, need for intervention 
and 30-day mortality.11 The review concluded that GBS has 
the highest sensitivity and specificity to predict this outcome 
compared with the other scores. The results of these studies were 
very consistent. Most confirmed that GBS was the best score 
to predict which patients require a hospital-based intervention, 
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including blood transfusion, endoscopic therapy and surgery. 
There is still room for improvement for GBS in predicting 
recurrent bleeding and 30-day or long-term mortality. With the 
large amount of clinical data providing consistent results, The 
working group recommend that GBS is used for predicting clin-
ical outcome of patients with NVUGIB. Patients with a score of 
0–1 rarely need any clinical intervention, and can thus be safely 
discharged, with elective endoscopy at a later stage. In contrast, 
a high score (say 10–12) is associated with frequent need for 
intervention such as transfusion and therapeutic endoscopy. The 
level of evidence was graded as high.
Statement 2: Patients with a GBS of<1can be treated as an 
outpatient
(Accept-agreement: 94.5%, level of evidence: high)
Most of the studies are very consistent in showing that GBS is 
the best tool to predict which patients presenting with UGIB 
are likely to require a hospital-based intervention. This first 
pertains to blood transfusion and also to the need for endoscopic 
treatment and surgery. Several studies also point to setting the 
threshold of GBS <1–3 as an indicator for patients not requiring 
hospitalisation.2 4–6 9–11
The Upper Gastrointestinal Haemorrhage International 
Consortium has examined the subject of threshold of GBS in 
managing UGIB. In their study recruiting patients from four 
countries (Scotland, England, Denmark and New Zealand), they 
found that the GBS at a cut-off point of <1 and <2 identified 
low-risk patients with a higher level of specificity than setting 
the cut-off value of GBS at 0 (40–49% vs 22%).12 The GBS at a 
cut-off value of <2 had the highest specificity to detect adverse 
outcomes but missed 3% of high-risk patients. Therefore, the 
authors suggested that a GBS cut-off point at <1 was most suit-
able as a guide for outpatient management.12 Some argue that 
even the GBS has a relatively low specificity to predict adverse 
outcomes.11 This comment is primarily based on a systematic 
review. The working group believe that by adopting a GBS 
cut-off point <1, most hospitals can reduce the majority of 
unnecessary hospital admissions without missing high-risk 
patients. It will naturally translate into a significant reduction 
in costs of managing UGIB. As we have pointed out in our 
previous consensus statement,1 a low risk for recurrent bleeding 
is not the same as low risk for mortality. Patients whose bleeding 
is controlled might still die owing to non-bleeding related causes 
such as cardiac and pulmonary decompensation.13 Therefore, 
the GBS score and its cut-off threshold cannot be interpreted 
as a score to predict mortality. The working group agreed that 
existing published data support this statement with a level of 
evidence graded as high.
Statement 3: Bloodtransfusion should be restricted in the 
management of upper gastrointestinal bleeding
(Accept—agreement: 100%, level of evidence: moderate)
It would seem uncontroversial to replace blood loss in UGIB 
by transfusion of red blood cell and plasma to restore and 
preserve tissue perfusion and blood pressure. The earliest 
study that suggested that blood transfusion might be harmful 
to patients with gastrointestinal haemorrhage was published 
over 30 years ago. A small group of patients with severe UGIB 
were randomised to receiving either a blood transfusion in 
cases of a haemoglobin <8 g/dL or shock, or transfusion of at 
least two units of blood regardless of haemoglobin level and 
haemodynamics.14 Early blood transfusion appeared to lead 
to more recurrent bleeding in these patients, and the authors 
suggested that this was due to reversal of hypercoagulable 
response to haemorrhage thereby encouraging rebleeding and 
hence the need for surgery.
Almost three decades later, a study from Spain randomised 
921 patients with severe acute UGIB to a restrictive blood 
transfusion strategy (transfuse only when haemoglobin 
level <7 g/dL) or a liberal transfusion strategy (transfuse 
only when haemoglobin <9 g/dL).15 Significant differences 
were demonstrated in the overall survival, further bleeding 
and adverse events between the two groups in favour of 
restrictive transfusion. The major difference, however, was 
seen in the group of patients with cirrhosis and Child-Pugh 
class A or B diseases.
A more recent study from the UK (TRIGGER Study) took 
a cluster randomised feasibility trial approach in six hospi-
tals. A slightly different definition of restrictive transfusion 
strategy (when haemoglobin <8 g/dL) versus liberal transfu-
sion strategy (when haemoglobin <10 g/dL) was adopted.16 
Comparison of centres using different transfusion strate-
gies showed that there was no significant difference in clin-
ical outcome, including mortality, thromboembolic events, 
surgical or radiological intervention, therapeutic interven-
tion, length of hospital stay and serious adverse events.
In Asia, a study from Korea randomised patients to 
receive restrictive transfusion (haemoglobin <8 g/dL) or 
liberal transfusion (target haemoglobin >10 g/dL),17 and 
confirmed that restrictive transfusion was associated with 
less recurrent bleeding. Pooling these four studies together, 
a meta-analysis of randomised controlled trials concluded, 
admitting moderate heterogeneity of studies and over 90% 
of patients from two studies,15 16 that restrictive blood 
transfusion conferred a lower mortality (relative risk 0.65, 
95% CI 0.44 to 0.97) and lower rebleeding rate (relative 
rate 0.58, 95% CI 0.40 to 0.84).18 There was, however, no 
difference in thromboembolic events associated with blood 
transfusion.
A retrospective nationwide survey of 5861 hospital admis-
sions in Denmark showed that the number of units of red 
blood cells is a predictor of the need for repeated endoscopy, 
surgery and 30-day mortality.19 In Canada, a retrospective 
cohort of 1677 patients with UGIB found that transfusion of 
red blood cells within 24 hours of presentation was signifi-
cantly and independently associated with an increased risk 
of recurrent bleeding.20 Another retrospective cohort from 
Australia, which included 2228 patients with NVUGIB, also 
reported that blood transfusion of more than four units is 
associated with increased risk of further bleeding, but not 
with higher mortality.21
It should be pointed out that the mechanisms explaining 
why transfusion may lead to recurrent bleeding in NVUGIB 
are not known. Based on existing published data, the Asia-Pa-
cific Working Group recommended a restrictive transfusion 
strategy, without specifying whether the threshold should 
be 7 g/dL or 8 g/dL. Clinical discretion should be exercised 
when transfusion is given. In patients with active cardiovas-
cular disease, the role of transfusion needs to be individual-
ised based on assessment of blood loss and the cardiovascular 
status. In patients with massive active bleeding with dropping 
blood pressure, a more liberal transfusion strategy might be 
necessary. There is also an expectation that more data will 
allow a refinement of this recommendation. The level of 
evidence was agreed to be moderate.
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Statement 4: Platelet transfusion has no benefit for patients with 
upper gastrointestinal bleeding taking antiplatelet agents
(Accept—agreement: 88.9%, level of evidence: low)
Antiplatelet agents, including aspirin and thienopyridines (eg, 
clopidogrel), are increasingly used in patients with various 
cardiovascular and cerebrovascular conditions as primary and 
secondary prevention. As aspirin and thienopyridines cause 
irreversible blockage of platelet function for the lifespan of the 
platelet, approximately 8–10 days, their effects are expected to 
last for days after discontinuation of this medication in patients 
with acute UGIB. It is common practice to transfuse platelets 
in patients with acute UGIB while receiving antiplatelet agents 
despite having normal platelet count.
A case–control study compared patients with UGIB with or 
without platelet transfusion irrespective of platelet counts. It 
showed that platelet transfusion did not reduce bleeding but 
probably increased the overall mortality.22 The use of platelet 
transfusion was studied in another retrospective observational 
study comparing a group of patients with UGIB in the ICU 
for clinical outcome.23 There was no demonstrable differ-
ence in total hospital stay, amount of blood transfusion and 
resulting haemoglobin levels between the platelet-transfused 
and non-transfused group. The platelet-transfused patients, 
however, were found to have had a shorter stay in the ICU. In 
view of the absence of any demonstrable improvement in clin-
ical outcome, the working group did not recommend platelet 
transfusion in UGIB even if patients are taking antiplatelet 
agents. The working group considered the evidence for this 
recommendation weak and remarked that this statement 
applied only to patients with normal platelet counts.
endoscopic management
Statement 5: Patients with haemodynamic shock and signs of upper 
gastrointestinal bleeding should be offered urgent endoscopy after 
resuscitation and stabilisation
(Accept—agreement: 100%, level of evidence: moderate)
The timing of endoscopy in patients with NVUGIB is a 
matter of debate. The previous Asia-Pacific Working Group 
consensus recommended ‘endoscopic intervention within 
24 hours of onset of bleeding in patients at high risk”.1 A 
systematic review concluded that endoscopy within 12 hours 
did not improve clinical outcome.24 It has also been pointed 
out that in patients at very high risk who are haemody-
namically unstable and in patients presenting with massive 
haematemesis, endoscopy should be performed as soon as 
they are stabilised with resuscitation.
Several studies examined the role of urgent endoscopy 
(within 12 hours) in the management of NVUGIB. In a retro-
spective cohort of 361 patients, it was found that patients 
who underwent urgent endoscopy had a greater than five-
fold increased risk of adverse outcome (death, inpatient 
rebleeding, surgery or radiological intervention or repeated 
endoscopic therapy). In a subgroup analysis from this study, 
time to endoscopy was not significant as a predictor of worse 
outcome, hence less prognostic in the high-risk patients than 
in lower-risk patients.25 A nationwide cohort study included 
12 601 patients with peptic ulcer disease. It suggested that 
patients with haemodynamic instability or American Society of 
Anesthesiology score of 3–5 had reduced in-hospital mortality 
if receiving endoscopy within 6–24 hours after admission.26 
However, the exact timing within 24 hours is still not clear. 
A nationwide survey from the UK included 4478 patients. It 
showed that earlier endoscopy (<12 hours) was not associated 
with a lower mortality, or need for surgery, compared with 
endoscopy offered within 24 hours.27
Two studies from Asia also examined this question. In Singa-
pore, a cohort study showed that in high-risk UGIB patients 
with a GBS>12, timing of endoscopy is the most important 
factor associated with all-cause in-hospital mortality.28 The 
cut-off time of endoscopy that improved survival of such 
patients was within 13 hours from presentation. In contrast, a 
study from Hong Kong selected high-risk patients (GBS >12) 
for randomisation to urgent (within 6 hours of presentation) 
versus early (within 24 hours of presentation) endoscopy. 
This study did not confirm the benefit of very early endos-
copy.29 With endoscopy within 6 hours, patients had more 
active bleeding lesions requiring endoscopic haemostasis, but 
this conferred no benefit in prevention of recurrent bleeding, 
mortality, requirement of blood transfusion and duration of 
hospital stay. Urgent endoscopy within 6 hours of presenta-
tion for all NVUGIB seems unnecessary. The working group 
accepts that in some highly selected patients, such as those who 
present with haemodynamic shock or instability, an urgent 
endoscopy, say within 12 hours of admission, may benefit the 
patient after initial resuscitation and stabilisation. However, 
offering urgent endoscopy to all patients who present with 
NVUGIB is not considered necessary. The level of evidence is 
graded as moderate.
Statement 6: Endoscopic haemostatic powder spray (such as 
Hemospray) is useful as a stop-gap treatment in NVUGIB
(Accept—agreement: 83.3%, level of evidence: low)
The first human study of endoscopic haemostatic power 
spray in peptic ulcer disease was reported from Hong Kong.30 
In a small series of 20 patients with peptic ulcer bleeding, 
Hemospray stopped bleeding in 19 (95%) cases and recur-
rent bleeding occurred in 2 (10%). This initial success was 
echoed by a number of case series, in which the haemo-
static spray was used either as a monotherapy, an adjunctive 
therapy or as a salvage therapy.31–37 Most studies reported a 
relatively high success rate (80–95%), but also a relatively 
high recurrence rate of bleeding (range 10–40%). Endoscopic 
haemostatic powder is easy to use and associated with few 
adverse events. Haemostatic powder spray has also been used 
in patients receiving oral anticoagulants and showed similar 
success.38 When endoscopy is repeated on the next day, most 
of the haemostatic power is washed away leaving a clean and 
non-bleeding lesion for definitive treatment. Unfortunately, so 
far there is no randomised controlled trial (RCT) comparing 
the efficacy of haemostatic spray with any other endoscopic 
modality. Only smaller series and retrospective cohort studies 
are available. A RCT is eagerly awaited to confirm the efficacy 
of this treatment.
The working group recommends endoscopic haemostatic 
power spray as a useful treatment for temporary control of 
bleeding in NVUGIB when definitive haemostasis cannot be 
achieved. This includes situations such as lack of endoscopic 
expertise or when despite attempts of endoscopic haemostasis, 
bleeding still continues. Patients with bleeding from upper 
gastrointestinal malignancy may also be benefit from haemo-
static powder spray treatment. In view of the lack of RCTs and 
large-scale studies, the level of evidence was considered low.
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Statement 7: Over-the-scope-clipping devices (such as Ovesco) are 
useful in treating lesions refractory to conventional endoscopic 
haemostatic therapy
(Accept—agreement: 94.4%, level of evidence: moderate)
In contrast to haemostatic powder spray, the over-the-scope-clip 
(OTSC), if successfully applied, appears to provide a firm and 
definite control of bleeding in NVUGIB.
Made from nitinol alloy, the OTSC fits to the tip of the endo-
scope and can be deployed by tightening the thread with the 
hand wheel using a mechanism similar to rubber band variceal 
ligators. After being released from the applicator, the shape-
memory effect and elasticity of the alloy result in firm closure of 
the clip. Compared with conventional clips, the OTSC can take 
up much more tissue by grasping deeper layers of the gastroin-
testinal wall, and hence the device can be used to treat bleeding 
and bowel perforation.
Several case series reported promising results of successful 
haemostasis in the range of 70–100%.39–42 Recurrent bleeding 
within 7 days occurred in 5–33%. This device, however, is tech-
nically slightly more demanding than other through-the-scope 
haemostatic treatments. Deployment of the OTSC requires 
accurate positioning and adequate retraction of tissue (either by 
suction or retractor) into the cap of the OTSC before the clip can 
be released properly. The retractor or anchor device is used in 
hard fibrotic ulcers, especially those located in difficult positions 
such as the high lesser curvature of the stomach. It punctures the 
base of the lesion and allows tissue to be pulled into the cap. At 
certain locations in the stomach (eg, proximal lesser curve of the 
stomach) and duodenum (junction of the first and second part of 
the duodenum), this can be technically challenging.
A multicentre randomised control trial comparing through-
the-scope clips (TTSC) with OTSC has recently been reported,43 
In that study, 32 patients received TTSC and 33 received 
OTSC. Initial haemostasis was reported in 62.5% of those who 
received TTSC and 96.8% received OTSC (P=0.002). Recur-
rent bleeding within 7 days after treatment occurred at the same 
rate in both groups (33.3% vs 24.4%). The interim results of this 
study suggested that OTSC is a better haemostatic device than 
haemoclips in the treatment of peptic ulcer bleeding. In view of 
the promising interim results while waiting for a full report, the 
working group recommends the use of OTSC in treating lesions 
refractory to conventional endoscopic therapy, such as through-
the-scope haemoclips, thermal device or endoscopic injection. 
There may be a role for OTSC in primary therapy, especially 
in peptic ulcer bleeding with large vessels. This device will add 
to the armamentarium for NVUGIB, with the level of evidence 
graded as moderate.
Statement 8: Endoscopic treatment of delayed bleeding after 
endoscopic mucosal resection or endoscopic submucosal dissection 
is similar to that for bleeding peptic ulcers
(Accept—agreement: 89%, level of evidence: moderate)
As endoscopic mucosectomy (EMS) and endoscopic submu-
cosal dissection (ESD) are gaining popularity among tertiary 
centres worldwide, complications such as delayed bleeding 
require more guideline from experts. A meta-analysis which 
pooled data from over 70 studies (15 RCTs, three prospec-
tive trials, five prospective cohort studies, and 48 retrospec-
tive cohort and case–control studies) depicted clearly the 
risks associated with EMS and ESD.44 Post-ESD bleeding 
occurred in 5.1% (95% CI 4.5% to 5.7%) of patients. Risk 
factors identified included male gender, cardiac disease, the 
use of antithrombotic agents, chronic liver or kidney disease, 
tumour size >2 cm or resected specimen size >3 cm, lesions 
on the lesser curve, flat or depressed lesion and invasive carci-
noma. Procedure time was not a clear risk factor for post-ESD 
bleeding but the need for endoscopic haemostasis was a factor. 
Experienced practitioners of ESD stated that the management 
of post-ESD bleeding did not differ from that for peptic ulcer 
bleeding. Most post-ESD bleeding occurred within 24 hours 
after the procedure. Endoscopic devices used in peptic ulcer 
bleeding can also be used to treat post-ESD bleeding. Most 
post-ESD bleeds come from a focal bleeding point and are 
confined to mucosal and submucosal layers, without pene-
trating through the muscle layer. Hence, haemostasis in such 
circumstances is relatively easy. There is no agreement on 
whether proton pump inhibitors are better than histamine-2 
receptor antagonists after ESD.45 46 Second-look endoscopy 
has not been proved to be associated with less postproce-
dural bleeding,47 Overall, the working group concluded that 
post-EMS and post-ESD bleeds can be managed like peptic 
ulcer bleeds. The level of evidence was graded as moderate.
Post-endoscopic management
Statement 9: As an adjunct to endoscopic treatment, high-dose oral 
proton pump inhibitors can be used to prevent rebleeding
(Accept—agreement: 88.9%, level of evidence: moderate)
The use of intravenous high-dose proton pump inhibitors 
(PPIs) has become standard practice in the management of 
upper gastrointestinal bleeding. At least three randomised 
trials, all from South Asia, showed that oral PPIs, given with 
or without endoscopic therapy, also reduce the risk of recur-
rent bleeding from peptic ulcer.48–50 New evidence suggests 
that high-dose oral PPIs may have a similar effect to their 
action in preventing recurrent bleeding from peptic ulcers.
A study from Hong Kong recruited 118 high-risk patients 
with Forrest I or IIa/b peptic ulcer bleeding to receive 
either IV esomeprazole plus oral placebo or oral esomepra-
zole (40 mg every 12 hours) plus IV PPI placebo.51 Recur-
rent bleeding within 30 days was reported in 7.7% in the 
IV esomeprazole group and 6.4% in the oral esomeprazole 
group. There was no difference in the requirement for blood 
transfusion, repeated endoscopic therapy and hospital stay 
between the two groups. It was noted that the study was 
stopped prematurely and was not designed as an equivalent 
trial. The trend suggests that the action of high-dose oral 
PPI peptic ulcer bleeding is comparable to that of IV PPI. In 
Taiwan, IV esomeprazole was compared with oral lansopra-
zole (30 mg four times a day for 3 days) in patients with peptic 
ulcer bleeding.52 There was no difference in all the clinical 
outcome parameters, except that those who received oral PPI 
had a shorter hospital stay. In Korea, when IV omeprazole 
was compared with oral rabeprazole (20 mg twice daily), the 
recurrent bleeding rate, surgical intervention and mortality 
between the two groups were comparable.53
There is no properly powered RCT to confirm that high-
dose oral PPI is as effective as IV PPI. The working group 
accepted that high-dose oral PPI can be used to prevent recur-
rent bleeding, but emphasised that it has to be used as an 
adjunct to endoscopic therapy. Only after endoscopic haemo-
stasis is achieved, can high-dose oral PPI be recommended 
to prevent recurrent bleeding. The definition of high-dose 
oral PPI has been stated as at least 80 mg of esomeprazole (or 
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equivalent dosage of other PPIs). The high oral dose should be 
maintained for at least 3 days, which is the period of highest 
risk of recurrent bleeding. If the patient’s condition remains 
stable, standard dose oral PPI can be resumed afterwards. All 
the reports were relatively small and underpowered, and thus 
the level of evidence was graded as moderate, in the hope that 
future studies might confirm this finding.
Statement 10: There is no special preference for a particular proton 
pump inhibitor when used concomitantly with clopidogrel
(Accept—agreement: 94%, level of evidence: moderate)
Concern about a potential interaction between PPIs and 
clopidogrel (a prodrug that requires CYP450 for metab-
olism) arose from a number of in vivo platelet aggregation 
studies.54 55 Different PPIs may have unequal effects on 
clopidogrel metabolism, which further intensifies the debate 
about a potential interaction between PPIs and clopidogrel. It 
has been suggested that PPIs such as lansoprazole, pantopra-
zole and rabeprazole have less interaction with clopidogrel 
since they have fewer inhibitory effects on CYP2C19.56–59 
More data suggest that concomitant use of a PPI with clopi-
dogrel increases the risk of major adverse cardiovascular 
events (MACE) in patients with high cardiovascular risk.
A retrospective cohort study from China, including about 
6200 patients who received aspirin plus clopidogrel with 
a PPI, reported that PPI users had a 3% increase in MACE 
compared with non-users.60 Another retrospective cohort 
from Italy reported an alarming 12% increase in MACE in 
patients receiving a PPI in conjunction with clopidogrel.61
PPIs interact with clopidogrel in patients with coronary, 
cerebrovascular and peripheral artery disease. This interac-
tion was implicated in the Factores de Riesgo y ENfermedad 
Arterial (FRENA) Registry as leading to a doubling of the 
incidence of myocardial infarction and ischaemic stroke.62 
However, a number of studies showed otherwise. A Japa-
nese study of patients with coronary stenting receiving dual 
antiplatelet agents showed no effect of PPIs on MACE or 
mortality.63 The safety of prescribing a PPI with clopidogrel 
was also suggested in a case–control study enrolling 23 655 
patients from the Netherlands.64 Beside cardiovascular risk, 
the safety profile of using a PPI concomitantly with clopido-
grel was also confirmed in group of 2765 patients who had 
strokes.65
Finally, the strongest support came from the only RCT, 
the Clopidogrel and the Optimisation of Gastrointestinal 
Events Trial (COGENT).66 Patients receiving dual anti-
platelet therapy (aspirin and clopidogrel) were randomised 
to receive omeprazole or placebo. Omeprazole significantly 
reduced rates of composite gastrointestinal events from 2.7% 
(without omeprazole) to 1.2% (with omeprazole). There was 
no significant excess of cardiovascular events in 3759 high-
risk cardiovascular patients recruited in this study. Although 
the trial was terminated prematurely, the follow-up period 
was sufficient to demonstrate the rate of MACE related to 
the medication. These data from COGENT, the only large-
scale RCT evaluating the effects of PPI on clinical endpoints 
in patients requiring dual antiplatelet therapy, provided reas-
surance about the safety of PPIs in high-risk cardiovascular 
subjects.67 Therefore, the working group recommended the 
use of a PPI without preference for a particular type, in patients 
requiring gastrointestinal protection against dual antiplatelet 
therapy. The level of evidence was considered moderate as 
only one RCT has been carried out, with limitations.
Statement 11: Routine second-look endoscopy is not recommended 
for patients after gastric endoscopic submucosal dissection
(Accept—agreement: 88.9%, level of evidence: high)
Submucosal arterioles are often exposed after gastric ESD 
just above the level of muscularis propria. As mentioned 
above, the management of post-ESD haemorrhage is similar 
to that for bleeding peptic ulcers. However, the pathology 
is different as the artificial ulcers created by ESD have less 
fibrosis and hence it is easier to stop bleeding using either 
a thermal or mechanical device. In this situation, routine 
second-look endoscopy may not be necessary. 
A single-centre randomised trial comparing routine 
second-look endoscopy with no second-look endoscopy 
after gastric ESD in 155 patients demonstrated no differ-
ence in recurrent bleeding and need for transfusion.68 Two 
prospective randomised trials including larger (>35 mm) arti-
ficial ulcers after gastric ESD also showed no difference in 
outcome between those with and without second-look endos-
copy.69 70 Another large multicentre prospective randomised 
trial conducted in Japan, including 262 patients, further 
demonstrated that routine second-look endoscopy confers no 
protection against recurrent haemorrhage.71 This result was 
confirmed by a meta-analysis including four randomised trials 
and four non-randomised trials. No difference in post-ESD 
bleeding rate was shown by the pooled data between those 
who did and did not receive second-look endoscopy.47 The 
panel concurred with high agreement that based on current 
evidence, routine second-look endoscopy is not recommended 
for patients after gastric ESD, with a level of evidence graded 
as high.
Statement 12: Among patients with high cardiothrombotic risk 
receiving antiplatelet agents, these agents should be resumed as 
soon as haemostasis can be established
(Accept—agreement: 100%, level of evidence: high)
Patients with NVUGIB taking antiplatelet agents face a 
dilemma of discontinuing these drugs to facilitate controlling 
of haemorrhage or to continue taking these drugs to avoid 
thromboembolic complications. Using the UK primary care 
database, a study reported the cardiovascular and UGIB conse-
quences of low-dose acetylsalicylic acid (ASA) in patients aged 
50–84 years.72 Based on this dataset, the attributable risks 
associated with ASA discontinuation for non-fatal myocar-
dial infarction/coronary death and ischaemic stroke were 17 
and 11 per 1000 people, respectively. On the other hand, the 
risk of UGIB with continued ASA was 1.6 per 1000 people. 
This amounts to eight extra cardiovascular events for a reduc-
tion of 0.4 UGIB events per year.
The only RCT examining this subject was reported by the 
Hong Kong group. It showed that immediate resumption of 
aspirin for high-risk cardiac patients was critical as it did 
not increase the risk of fatal haemorrhage but significantly 
improved the 30-day survival.73 Subsequently, a retrospec-
tive analysis of 118 patients who received low-dose aspirin 
with 40% of cases discontinuing the drug for 2 years showed 
a sevenfold increase in risk for a cardiovascular event and 
cardiac death.74 A study from Taiwan comparing 89 patients 
receiving esomeprazole alone versus 89 patients receiving 
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esomeprazole plus aspirin showed that the ulcer healing rate 
between the groups was almost identical. There is no evidence 
to suggest that aspirin would delay the healing of peptic ulcer 
when treated with a PPI.75 It should be noted that these two 
studies used a relative low dose of aspirin (80–100 mg daily). 
Even at this dose, the cardioprotective effects of aspirin 
are retained and haemorrhagic complications are not detri-
mental. Similarly, although data are lacking on non-aspirin 
antiplatelet agents, the protective effects against thromboem-
bolic events in cardiovascular and cerebrovascular diseases 
are considered more important than the increased risk of 
gastrointestinal bleeding.
No study has investigated the optimal timing for the resump-
tion of antiplatelet agents, but one can consider resuming 
these agents on day 1 if endoscopy shows a clean-based ulcer. 
In patients who received endoscopic therapy for bleeding, 
antiplatelet agents can be resumed 72 hours after the treat-
ment—that is, passing the period of highest risk for recur-
rent bleeding. The working group unanimously endorsed this 
recommendation of resuming antiplatelet agents early when 
UGIB is under control. The level of evidence of this statement 
was considered as high.
Statement 13: In patients receiving dual antiplatelet agents, at 
least one antiplatelet agent should be resumed in cases of upper 
gastrointestinal bleeding
(Accept—agreement: 94.4%, level of evidence: low)
The most commonly used antiplatelet agents are ASA 
(aspirin), a cyclo-oxygenase inhibitor and thienopyridines 
that bind to P2Y12 component of the adenosine diphos-
phate receptors. After stopping ASA, 7–9 days are required 
to regain full platelet function, whereas in the case of thien-
opyridines (such as clopidogrel or prasugrel), the minimum 
duration to restore platelet function is 5–7 days. Use of dual 
antiplatelet agents, often ASA plus a thienopyridine, may 
confer a threefold increase in the risk of UGIB over single-
agent antithrombotic therapy.76 There are no data guiding the 
management of these patients using dual antiplatelet therapy 
when they develop UGIB. We do not recommend withholding 
both antiplatelet drugs because the median time to coronary 
stent thrombosis can be as short as 7 days with both drugs 
withheld as compared with 122 days with only clopidogrel 
withheld.77 Balancing the risk and benefit of discontinuation 
of antiplatelet agents, the ASGE recommends that cessation 
of all antiplatelet therapy after PCI should be avoided, and 
furthermore, when only one antiplatelet agent is used, aspirin 
should be continued as it is associated with a lower risk for 
causing recurrent bleeding. On the other hand, for patients 
with a high risk of thrombosis, such as those with drug-eluting 
coronary stents, clopidogrel should not be discontinued for 
more than 5 days.78
Cardiologists’ opinion should be sought for the commence-
ment of antiplatelet agents. In patients with low risk of recur-
rent bleeding from the gastrointestinal tract, antiplatelet 
agents should not be discontinued at all. The working group 
consider that this statement is primarily based on pharmaco-
logical characteristics of the antiplatelet agents. Clinical trials 
to test the safety of this strategy are eagerly awaited. The 
level of evidence was considered low.
Statement 14: Among direct oral anticoagulant (DOAC) or warfarin 
users with high cardiothrombotic risk who develop ulcer bleeding, 
DOAC or warfarin should be resumed as soon as haemostasis is 
established
(Accept—agreement: 83.3%, level of evidence: low)
Clinical evidence is lacking to support strategies 
for managing patients with NVUGIB and high cardiothrom-
botic risk who receive DOAC or warfarin. For such patients 
with atrial fibrillation and/or valvular heart diseases, 
management should depend on the balance between throm-
botic risk and bleeding risk. In acute NVUGIB, DOAC or 
warfarin should be withheld to facilitate achievement of 
haemostasis.
If the patient is taking warfarin, four-factor prothrombin 
complex concentrate (PCC) and vitamin K or fresh frozen 
plasma can be given for life-threatening GI bleeding. Warfarin 
reversal should be used for life-threatening bleeding irrespec-
tive of the international normalised ratio (INR). Current 
evidence does not show any correlation between INR at 
presentation and outcomes of GI bleeding.79 A combination 
of PCC and vitamin K is preferred for urgent reversal of 
warfarin. PCC has advantages over fresh-frozen plasma such 
as faster onset of action and minimal risk of fluid overload. 
Endoscopic therapy should not be delayed in patients with 
serious UGIB. Warfarin and DOAC treatment should be with-
held in patients with ongoing NVUGIB.80
The Food and Drug Administration in October 2015 
granted approval for idarucizumab, a potent monoclonal 
antibody against dabigatran, for use in patients with uncon-
trolled bleeding. In a multicentre study of 503 patients with 
uncontrolled bleeding who were about to undergo an urgent 
procedure, 5 g of idarucizumab reversed the anticoagulant 
effect of dabigatran within 4 hours in almost all patients.81 
However, its true benefit in NVUGIB is still unclear because 
of limited clinical data.
Once the bleeding is controlled, the decision to resume 
anticoagulants should be made by a multidisciplinary team 
with cardiologist, gastroenterologist, intensivist and, if 
feasible, with patient’s participation. The CHA2DS2-VASC 
and HAS-BLED score are useful in assessing the need for 
continuing anticoagulation.82–84 In patients with high cardio-
vascular risk, resumption of anticoagulants should not be 
delayed. A large prospective cohort study of patients with 
atrial fibrillation in Denmark showed that resumption of 
single anticoagulants was associated with lowest rate of 
all-cause mortality85 Most data on vitamin K antagonists 
show that resuming the oral anticoagulant is associated with 
a lower mortality despite more frequent major bleeding.86 A 
recent study suggested that dabigatran offers similar protec-
tion against thromboembolism with less rebleeding than 
warfarin after major bleeding.87 The timing for resumption of 
warfarin should be assessed on a patient-by-patient basis. Since 
the time required for re-anticoagulation will be prolonged 
after warfarin reversal with vitamin K, we recommend early 
resumption of warfarin once haemostasis has been achieved, 
especially in patients with high thromboembolic risk. With 
DOAC, the effect should disappear in 1–2 days after stopping 
the drug. Therefore, once bleeding is under control, DOAC 
can be resumed earlier (within 1–2 days) bearing in mind that 
anticoagulation is achieved rapidly within hours and there-
fore might increase the risk of rebleeding. If early anticoagu-
lation is indicated in patients with high thromboembolic risk, 
a bridge approach with heparin or enoxaparin is useful. The 
working group considered that this recommendation is based 
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primarily on expert opinion without data from RCTs, hence 
the level of evidence was graded as low.
rejected statements
Statement 1: Video capsule endoscopy can be considered as a triage 
tool for patients who require early intervention
(Reject—agreement: 22.2%)
Modified: Capsule endoscopy can be considered as a triage tool for 
hospitalisation
(Reject—agreement: 39%)
The first attempt to use video capsule endoscopy (VCE) in 
assessment of patients with UGIB was conducted in a multi-
centre study in which patients received VCE, followed by naso-
gastric tube and then conventional endoscopy for evaluation of 
UGIB.88 Blood was detected significantly more often by VCE 
than by nasogastric tube aspiration. There was no difference in 
identification of peptic or inflammatory lesions between VCE 
and conventional endoscopy.
In view of this initial encouraging result, a prospective RCTwas 
carried out. Seventy-one patients with UGIB were randomised 
to receive either the standard-of-care treatment in hospital or a 
VCE in the emergency room (ER). The need to admit to hospital 
was determined by the findings of VCE.89 This study showed 
a reduction of hospital admission in the VCE group of >70% 
and with no serious adverse outcome. Comparison of the VCE 
results with GBS evaluation, showed also a significant reduction 
in hospital admission among the patients recruited to receive 
VCE in this RCT. Based on this result, the authors considered 
VCE in the ER a feasible triage tool to differentiate patients who 
do or do not require hospital admission.
Comparison of VCE and GBS and RS was conducted in 
another small-scale cohort study of 25 patients presenting with 
UGIB.90 VCE accurately predicted high-risk endoscopic stigmata 
and compared favourably with GBS and RS for risk stratifica-
tion. Training of ER physicians to interpret VCE images has 
also been found to be feasible in a survey study involving 126 
emergency department physicians.91 There are concerns about 
the costs of VCE used in such circumstances, but a cost-effective-
ness analysis comparing VCE with other strategies for managing 
UGIB showed that VCE was cost-effective for patients at low 
and moderate risk presenting to the ER with UGIB.92
However, VCE may not be optimal in examination of the 
duodenum. In a risk stratification study of UGIB from Australia, 
authors found that because of low duodenal visualisation, there 
was poor concordance between VCE and conventional endos-
copy in the findings of the bleeding source in patients with 
UGIB.93
Although the initial data look promising, the Asia-Pacific 
Working Group considered it premature at this stage to recom-
mend the use of VCE as a risk stratification method for UGIB or 
as a triage tool to decide on hospital admission. There is so far 
only one small-scale RCT supporting the use of VCE as a patient 
triage tool. Besides inadequate duodenal visualisation, the possi-
bility of missing lesions in the fundus of the stomach and other 
less accessible sites is a concern. The logistics of setting up VCE 
in the ER, and of training personnel to interpret the video bring 
further uncertainties. There were also concerns that VCE at the 
ER might delay endoscopy for those who require endoscopic 
intervention. The working group did not accept VCE as a triage 
tool and would like to await further clinical studies to prove its 
value.
Statement 2: Pre-endoscopy intravenous proton pump inhibitors are 
recommended in stable patients awaiting endoscopy
(Reject—agreement: 72.2%)
Modified: Intravenous proton pump inhibitors are recommended 
for patients with suspected gastrointestinal bleeding awaiting 
endoscopy
(Reject—agreement: 66%)
There are now at least six RCTs, comprising 2223 patients with 
UGIB being studied for the benefit of pre-endoscopy intravenous 
PPIs.94–99 With PPIs, the stigmata of haemorrhage will be down-
graded and hence endoscopic therapy less frequently needed, yet 
there is no reduction in recurrent bleeding, surgery and overall 
mortality between PPI and control treatment. The Cochrane 
review which pooled these six studies concluded that PPI treat-
ment before endoscopy might reduce the proportion of patients 
requiring endoscopic therapy without affecting clinically signifi-
cant outcomes.100 It is possible that the overall costs of treatment 
and the need for experienced endoscopists could be reduced; 
however, the clinical impact is uncertain.
The working group noted that many physicians use intrave-
nous PPIs for patients presenting in stable conditions with symp-
toms suggestive of UGIB, while waiting for endoscopy. These are 
commonly administered at the ER or at primary care clinics. This 
statement pertains to patients who are ‘stable’ or ‘suspected’ of 
UGIB waiting for endoscopy. The working group members voted 
to reject indiscriminate use of IV PPIs in such circumstances as there 
is no proven value. Indiscriminate use of IV PPIs will increase the 
cost of managing NVUGIB. This statement should be read differ-
ently from the previous Asia-Pacific Working Group consensus 
which stated that pre-endoscopy PPI is recommended where early 
endoscopy or endoscopic expertise is not available within 24 hours.1 
When endoscopy facilities or endoscopy expertise are not available 
within 24 hours, downgrading stigmata of recent haemorrhage and 
reducing the requirement for endoscopic intervention becomes 
much more justified.
Statement 3: Angiographic embolisation should be applied in 
patients with high-risk ulcers to prevent recurrent ulcer bleeding
(Reject—agreement: 38.9%)
When endoscopic haemostasis fails to control peptic ulcer bleeding, 
repeated endoscopy and surgery are considered viable options to 
control bleeding. There is little evidence to support the use of angio-
graphic embolisation as an alternative to surgery after endoscopic 
treatment has failed except for two retrospective studies.101 102 A 
Scandinavian study prospectively randomised 105 patients with 
peptic ulcer bleeding to arterial embolisation after endoscopic 
therapy or to standard treatment.103 The authors used a composite 
endpoint which included transfusion requirement, development of 
rebleeding, need for haemostatic intervention and mortality as the 
primary endpoint. While there was a trend towards less rebleeding 
for those who received angiography, the study reported no differ-
ence in the outcome of those who received angiography versus stan-
dard treatment.
More recently a prospective randomised trial in Hong Kong 
tried to examine this by allocating patients with Forrest I/II 
peptic ulcer bleeding to pre-emptive angiographic embolisation 
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or standard-of-care management without embolisation.104 In the 
intention-to-treat analysis, there was no demonstrable difference 
between the two groups in recurrent bleeding within 30 days, need 
for further endoscopic or surgical interventions, hospital stay, blood 
transfusion requirement and mortality. In the per protocol analysis 
of 90 patients who received angiographic embolisation compared 
with 113 patients who did not, there a trend favouring angiography, 
with a significant reduction in mortality. The size of ulcer (>1.5 cm) 
is the best predictive parameter associated with benefit of angiog-
raphy. However, this is a single study with a marginal benefit. The 
working group considered it premature to recommend angiography 
to prevent recurrent bleeding from peptic ulcer after endoscopic 
treatment. More evidence from future clinical trials is necessary.
Statement 4: A risk stratification score should be used to identify 
high-risk bleeding ulcers after endoscopic therapy for second-look 
endoscopy
(Reject—agreement: 55.6%)
Modified: A risk stratification score may be useful to identify 
high-risk bleeding ulcers after endoscopic therapy for second-look 
endoscopy
(Reject—agreement: 23%)
Recurrent bleeding occurs in 8–15% of patients with peptic ulcer 
bleeding and is associated with a two- to fivefold increase in 
mortality. The objective of routine second-look endoscopy, usually 
performed within 24 hours after index endoscopy, is to pre-emp-
tively treat peptic ulcers with persistent stigmata of recent haemor-
rhage before they start bleeding again.
Second-look endoscopy was first investigated for its efficacy in 
prevention of peptic ulcer rebleeding by a few prospective randomised 
trials in the 1990s.105–108 The results from these randomised trials 
were conflicting. Some showed that second-look endoscopy and 
repeated endoscopic haemostasis were effective in preventing recur-
rent haemorrhage107 108 while others demonstrated no efficacy.105 106 
The reasons for these conflicting results included recruitment of 
patients with different levels of rebleeding risk, a non-standardised 
method of primary haemostasis and variation in the performance of 
second-look endoscopy. A meta-analysis based on eight prospective 
randomised trials concluded that second-look endoscopy reduced 
rebleeding in the absence of high-dose PPI especially in patients at 
very high risk.109 Analysis of these pooled data also suggested that 
second-look endoscopy reduced the need for surgery but had no 
significant effect on mortality. However, after removing two trials 
that included patients with a high risk of rebleeding, no benefit from 
second-look endoscopy was found.109 110 A recent randomised trial 
compared intravenous PPI infusion with second-look endoscopy in 
patients after receiving endosocopic haemostasis for peptic ulcer 
bleeding.110 It demonstrated no difference in recurrent bleeding, 
need for surgery and mortality between the two treatment strat-
egies. Furthermore, second-look endoscopy did not appear to be 
cost-effective when offered to all patients.
The question remains whether risk stratification with selection of 
high-risk patients may lead to a benefit from second-look endoscopy 
on the next day and with repeated treatment in case of persistent 
stigmata. The Baylor Bleeding Score attempted to select high-risk 
patients to receive second-look endoscopy versus controls and 
found a 24% difference in rate of recurrent bleeding.111 A study 
including 699 patients from Korea showed that use of a non-ste-
roidal anti-inflammatory drug, large transfusion volume and failure 
to perform second-look endoscopy were risk factors for recurrent 
bleeding after endoscopic therapy.112 Another study from Taiwan 
which enrolled 316 patients receiving a high-dose PPI after endo-
scopic therapy attempted to formulate a predictive score using 
endoscopic monotherapy and serum albumin levels.113 By this 
score, the receiver operating characteristic curve to predict need 
for second-look endoscopy appeared promising, but outcome data 
were lacking. To date, there is still a lack of evidence to suggest 
that any risk stratification method is effective in selecting patients 
at high risk who would benefit from second-look endoscopy and 
pre-emptive treatment.
The working group therefore rejected the statement that a risk 
stratification score may be useful to identify high-risk bleeding 
ulcers after endoscopic therapy for second-look endoscopy. 
Future studies should be conducted to verify the use of a risk 
stratification system.
Statement 5: A Doppler endoscopic probe should be used to guide 
endoscopic therapy in order to ensure adequate haemostasis
(Reject—agreement: 66%)
The use of a Doppler endoscopic probe is not new. Previous studies 
have shown that the technique requires skill and the results are often 
irreproducible. A study from the CURE group has recently reported 
that the Doppler endoscopic probe (DEP) can demonstrate major 
stigmata of peptic ulcer bleeding (spurting ulcer, blood clot and 
visible vessel) and had a significantly higher rate of detecting arterial 
blood flow than oozing ulcer and ulcer with flat pigmented spot.69 
The authors proposed that DEP can improve risk stratification in 
the management of peptic ulcer bleeding. This DEP is a FDA-ap-
proved disposable probe (Vascular Technology, Nashua, New 
Hampshire, USA) that can be inserted into the working channel of 
the gastroscope. Subsequently, the same group compared the stan-
dard endoscopic treatment (using a thermal or mechanical device 
with or without injection) with endoscopic treatment guided by 
DEP.114 Endoscopic haemostasis was applied to peptic ulcers until 
DEP showed no Doppler signal of residual blood flow. The results 
showed that with DEP-guided therapy, recurrent bleeding can be 
reduced from 26.3% to 11.1%. However, because of the small 
number of patients with significant events, there was no difference 
demonstrated in requirement for surgery or angiography to salvage 
uncontrolled bleeding, and there was no reduction in mortality. 
Although a remarkable RCT, the working group concluded that it 
is too early to recommend DEP for the management of UGIB. This 
is based on the argument that only a single study from a renowned 
referral centre demonstrated the benefit of this skill-demanding 
technique. The working group opined that more data, from other 
centres recruiting more patients, are required to confirm the value 
of DEP.
ConClusion
Since the last Asia-Pacific consensus on NVUGIB published 7 years 
ago, significant advancement has been made in the clinical manage-
ment of patients before endoscopy (risk stratification scores, blood 
and platelet transfusion, use of PPIs) and in the development of 
endoscopic haemostasis (haemostatic powder spray and over-the-
scope clips). Emerging techniques, such as the use of capsule endos-
copy for patient triage, a Doppler endoscopic probe for assessing 
adequacy of endoscopic therapy, and the pre-emptive use of angio-
graphic embolisation, look promising but require further evalua-
tion. The use of PPIs has been further clarified, showing that routine 
use of IV PPI is unnecessary but high-dose oral PPI after endoscopy 
may be beneficial. Experience in managing NVUGIB after EMR and 
ESD is accumulating. An emerging problem is the increasing use of 
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double antiplatelet agents and direct oral anticoagulants in patients 
with cardiac and cerebrovascular diseases, and clinical data to guide 
management are still minimal. Resumption of antiplatelet agents or 
anticoagulants is important but the timing and choice of drugs to 
be resumed require further clinical trials for guidance.
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